US Edition
Maker Suggests Wegovy Lowers Heart Risks More than Similar Drugs
A study of over 21,000 patients found Wegovy users had a 57% greater reduction in heart attack, stroke, or death risk compared to tirzepatide users, researchers said.
- On Sunday, Novo Nordisk presented findings that Wegovy may lower heart attack, stroke or death risk more than similar drugs at the European Society of Cardiology Congress in Madrid.
- Researchers analyzed medical records for more than 21,000 patients with obesity and heart disease to compare Wegovy with tirzepatide.
- The study found that patients with obesity and heart disease taking Wegovy had 15 cardiovascular events and saw a 57% greater reduction in heart-related risks than tirzepatide users, including a 29% lower risk when accounting for medication pauses over 30 days.
- The results remain preliminary and have not yet been peer-reviewed or published, and as of Monday Eli Lilly had not yet responded to the findings presented at the European Society of Cardiology Congress.
- Novo Nordisk argued that semaglutide `stands apart` with proven cardiovascular benefits for obesity patients, and GLP-1 drugs may offer varying heart protection levels if confirmed.
Insights by Ground AI
Does this summary seem wrong?
16 Articles
16 Articles
The Laconia Daily Sun+11 Reposted by 11 other sources
Wegovy Linked To Lower Heart Risks Than Similar Drugs, Study Shows
Key Takeaways
Pharma Pulse: Amgen Invests $600M in Innovation Hub, Novartis Collaborates With Argo, and Wegovy Tops Tirzepatide in Heart Outcomes
This episode of Pharma Pulse covers Amgen’s $600 million investment in a new California R&D center, Novartis’s collaboration with Argo Biopharmaceuticals to boost its cardiovascular pipeline, and new data showing Wegovy outperforming tirzepatide in reducing major adverse cardiovascular events.
Coverage Details
Total News Sources16
Leaning Left4Leaning Right1Center3Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 38%
13%
Factuality
To view factuality data please Upgrade to Premium
